1. Home
  2. SWTX vs IAG Comparison

SWTX vs IAG Comparison

Compare SWTX & IAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SWTX
  • IAG
  • Stock Information
  • Founded
  • SWTX 2017
  • IAG 1990
  • Country
  • SWTX United States
  • IAG Canada
  • Employees
  • SWTX N/A
  • IAG N/A
  • Industry
  • SWTX Biotechnology: Pharmaceutical Preparations
  • IAG Precious Metals
  • Sector
  • SWTX Health Care
  • IAG Basic Materials
  • Exchange
  • SWTX Nasdaq
  • IAG Nasdaq
  • Market Cap
  • SWTX 3.5B
  • IAG 4.1B
  • IPO Year
  • SWTX 2019
  • IAG 1996
  • Fundamental
  • Price
  • SWTX $46.67
  • IAG $7.47
  • Analyst Decision
  • SWTX Buy
  • IAG Buy
  • Analyst Count
  • SWTX 7
  • IAG 7
  • Target Price
  • SWTX $56.86
  • IAG $7.92
  • AVG Volume (30 Days)
  • SWTX 4.9M
  • IAG 15.8M
  • Earning Date
  • SWTX 05-09-2025
  • IAG 05-06-2025
  • Dividend Yield
  • SWTX N/A
  • IAG N/A
  • EPS Growth
  • SWTX N/A
  • IAG 405.77
  • EPS
  • SWTX N/A
  • IAG 1.42
  • Revenue
  • SWTX $219,670,000.00
  • IAG $1,771,200,000.00
  • Revenue This Year
  • SWTX $79.29
  • IAG $49.23
  • Revenue Next Year
  • SWTX $70.79
  • IAG $8.82
  • P/E Ratio
  • SWTX N/A
  • IAG $5.27
  • Revenue Growth
  • SWTX 730.42
  • IAG 61.05
  • 52 Week Low
  • SWTX $28.21
  • IAG $3.44
  • 52 Week High
  • SWTX $62.00
  • IAG $8.38
  • Technical
  • Relative Strength Index (RSI)
  • SWTX 60.85
  • IAG 62.64
  • Support Level
  • SWTX $46.21
  • IAG $6.68
  • Resistance Level
  • SWTX $46.77
  • IAG $7.15
  • Average True Range (ATR)
  • SWTX 0.15
  • IAG 0.25
  • MACD
  • SWTX -0.05
  • IAG 0.07
  • Stochastic Oscillator
  • SWTX 85.71
  • IAG 93.67

About SWTX SpringWorks Therapeutics Inc.

SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.

About IAG Iamgold Corporation

Iamgold Corp is a mid-tier gold mining company. The company operating gold mines are divided into geographic segments such as Cote Gold mine - Canada, Burkina Faso - Essakane mine, Westwood mine - Canada. The company's s non-gold mine segments are Exploration and evaluation and development, and Corporate - which includes royalty interests. The company generates the majority of its revenue from the Cote Gold mine segment.

Share on Social Networks: